Scilex Holding Company (SCLX) Stock

Healthcare · Drug Manufacturers - General · Member of Other US Stocks

Scilex Holding Company (SCLX) closed at USD 2.85 on 2026-10-14, a change of -74.8 % over the past year, with a market capitalization of USD 19.84M.

Scilex Holding Company recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Scilex Holding Company key figures

Previous close

USD 2.85 (2026-10-14)

1-year change

-74.8 %

Market cap

USD 19.84M

Enterprise value

USD 123.08M

P/E ratio (trailing)

-0.06

P/E ratio (forward)

3.86

EPS (trailing)

-48.83

EPS (forward)

0.73

PEG ratio

n/a

Price to book

-0.06

Revenue growth

-22.8 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.67

Employees

34

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Scilex Holding Company

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Scilex Holding Company and compare it with other stocks.